Posters Presented:

Government Benefits / Medicaid

Hepatitis-C/ HIV / Virology

Insomnia And Sleep Disorders

IVR Systems

Multiple Sclerosis

Pain

Persistence and Compliance

Quintile Analysis

Respiratory - Asthma, COPD, Respiratory Distress Syndrome

Rheumatoid Arthritis

Manuscripts Published:

Good Research Practices

Hepatitis C

Insomnia and Sleep Disorders

Multiple Sclerosis

Rheumatology: Rheumatoid Arthritis and Gout

Women's Health (Endometriosis)

Posters Presented:

Depression:

Brook RA, Roy S, Kleinman NL, Cifaldi MA. Impact of Rheumatoid Arthritis on Health Care Costs and Work Productivity: A Comparative Assessment With Diabetes and Depression, Ann Rheum Dis 2011;70(Suppl3):189) Ann Rheum Dis 2011;70(Suppl3):189).

Diabetes:

Brook RA, Kleinman NL, Wingenbach D, Bron MS, Baran RW. Medication Adherence and the Direct Medical and Prescription Cost Impact of Fixed vs Loose Dose Thiazolidinedione Combination Products Among Type 2 Diabetes Patients. Presented at the Academy of Managed Care Pharmacy 20th Annual Meeting & Showcase, San Francisco, CA, Moscone West Convention Center, April 16-19, 2008. J Manag Care Pharm. Mar 2008;14(2):235-236

Brook RA, Kleinman NL, Wingenbach D, Bron MS, Pandya B, Baran RW. Medication Possession Ratio and Health Benefit Cost Comparisons in Type 2 Diabetic Patients using Fixed and Loose Dose Thiazolidinedione Combination Products. Presented at the American Diabetes Association Annual Meeting June 7-9, 2008, San Francisco, CA. Diabetes. June 2008; 57 (sup 1): a346

Hepatitis-C/ HIV / Virology:

Brook RA, Kleinman NL, Melkonian AK, Smeeding JE. Comparisons of Relative Risks of Serious Comorbidities Among Employees with and without Insomnia, GERD, Hepatitis C, Multiple Sclerosis and Chronic Constipation. Presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 13th Annual International Meeting,May 5, 2008 Toronto, Ontario, Canada. Value Health. May 2008:11(3):A44.

Brook RA, Kleinman NL, Melkonian AK, Smeeding JE. Comparisons of Employee Workers’ Compensation Costs and Absence Days Using a National Database.Value Health 2010;13(3):A90

Su J, Kleinman NL, Brook RA, Melkonian AK, Smeeding JE, Corey-Lisle P. The Impact of Hepatitis-C Viral (HCV) Treatment on Work Absence and Productivity. Selected for poster presentation during Digestive Disease Week 2009 Chicago, IL, May 30 - June 4, 2009. Gastroenterology. May 2009:16(5) Suppl, M1810.

Brook RA, Kleinman NL, Melkonian AK, Smeeding JE. Comparisons of Employee Workers’ Compensation Costs and Absence Days Using a National Database. J Manag Care Pharm. March 2010; 16(2):145-6

Brook RA, Kleinman NL, Smeeding JE. Comparison of Direct Medical Costs and Services by Point of Service and Prescription Cost for Persons With Hepatitis-C With and Without Treatment. Value Health 2011:14(3):A181

Baran RW, Brook RA, Kleinman NL, Beren IA, Dietz B. Employees Living with Human Immunodeficiency Virus (HIV): Impact of Disease and Antiretroviral Therapies on Healthcare Costs and Productivity J Manag Care Pharm. March 2012; 18(2):174.

Multiple Sclerosis:

Kleinman NL, Brook RA, Rajagopalan K, Melkonian AK. Absenteeism (lost time) Among Employees with Multiple Sclerosis. Presented at Academy of Managed Care Pharmacy 20th Annual Meeting & Showcase, San Francisco, CA, Moscone West Convention Center, April 16-19, 2008. J Manag Care Pharm. March 2008;14(2):205-206

Brook RA, Rajagopalan K, Kleinman NL, Melkonian AK. Prevalence and Costs of Comorbidities Among Persons with and without Multiple Sclerosis: An Analysis of the AHRQ Major and Specific Diagnostic Categories. Presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 13th Annual International Meeting, May 5, 2008 Toronto, Ontario, Canada. Value Health. May 2008:11(3):A136.

Kleinman NL, Rajagopalan K, Brook RA, Melkonian AK. Severity of Illness Among Persons with Multiple Sclerosis: An Analysis of Cost Quintiles. Presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 13th Annual International Meeting to be presented during Poster Session #1, May 5, 2008 Toronto, Ontario, Canada.Value Health. May 2008:11(3):A141-142

Brook RA, Kleinman NL, Rajagopalan K, Melkonian AK. The Impact of Multiple Sclerosis On Absenteeism. Presented the Consortium of MS Center’s 22nd Annual Meeting, May 28-30, 2008, Denver, CO. Int J of MS Care. May 2008; 10(Supp 1): 11.

Kleinman NL, Rajagopalan K. Brook RA, Melkonian AK. Health Benefit Costs Among Employees With Multiple Sclerosis. Presented at the Consortium of MS Center’s 22nd Annual Meeting, May 28-30, 2008, Denver, CO. Int J of MS Care. May 2008; 10(Supp 1): 20-21.

award

Brook RA, Rajagopalan K, Kleinman NL, Beren I. Direct Medical Costs and the Likelihood of Health Service Utilization Before and After Initiation of Avonex (Interferon β1a IM) Treatment Among Persons with Multiple Sclerosis (MS). Presented at the Consortium of MS Center’s 23rd Annual Meeting, May 27-30, 2009, Atlanta, GA. 2009 CMSC Scientific Abstract Listing, CMSC:S111, page 149.

Brook RA, Rajagopalan K, Kleinman NL, Beren IA. Medication adherence with Disease modifying treatments for multiple sclerosis: Findings from a US National database of employees. Presented at ISPOR, October 26, 2008, Paris, France. Value Health;2009;13:A371

Cancer:

Fuldeore MJ, Brook RA, Smeeding JE, Dabbous OH. Persistence with Leuprolide Acetate in patients with Prostate Cancer. Presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 13th Annual International Meeting, May 5, 2008 Toronto, Ontario, Canada.Value Health. May 2008:11(3):A73.

Comparative Data:

Brook RA, Kleinman NL, Smeeding JE. Cost, Absences, Prevalence and Impact of Bipolar Disorder, Other Mental Disorders, Chronic Constipation, Functional Dyspepsia, Gastroesophageal Reflux Disease, Gout, And Insomnia. J Manag Care Pharm, September 2011; 17(7):556.

Persistence and Compliance:

Brook RA, Kleinman NL, Wingenbach D, Bron MS, Baran RW. Medication Adherence and the Direct Medical and Prescription Cost Impact of Fixed vs Loose Dose Thiazolidinedione Combination Products Among Type 2 Diabetes Patients. Presented at the Academy of Managed Care Pharmacy 20th Annual Meeting & Showcase, San Francisco, CA, April 16-19, 2008. J Manag Care Pharm. Mar 2008;14(2):235-236

Bipolar Disorder:

Kleinman N, Brook RA, Gardner H, Rajagopalan K, Smeeding JE. Incremental Health Benefits Cost of Bipolar Disorder among Insured Employees. Presented at the Academy of Managed Care Pharmacy 17th Annual Meeting and Showcase, April 22nd, 2005, Denver CO. J Manag Care Pharm. 2005. April;11(3):273-274

Kleinman N, Rajagopalan K, Brook RA, Smeeding JE, Gardner H. Physical and Mental Comorbidities among Employees with Bipolar Disorder: Analysis of AHRQ 261 Specific Categories. Presented at the Academy of Managed Care Pharmacy 17th Annual Meeting, April 22nd, 2005, Denver CO. J Manag Care Pharm. 2005 April;11(3):279

Kleinman N, Gardner H, Rajagopalan K, Brook RA, Smeeding JE. Physical and Mental Comorbidities among Employees with Bipolar Disorder: Analysis of Major Diagnostic Categories. Presented at the American Psychiatric Association Annual Meeting, May 24th, 2005. Atlanta, GA. 2005 Annual Meeting New Research Abstracts

Kleinman N, Brook RA, Gardner H, Rajagopalan K, and Smeeding JE. Incremental Health Benefits Cost of Bipolar Disorder among Insured Employees. Presented at the American Psychiatric Association Annual Meeting, May 24th, 2005. Atlanta, GA. 2005 Annual Meeting New Research Abstracts

Kleinman N, Rajagopalan K, Brook RA, Smeeding JE, and Gardner H. Physical and Mental Comorbidities among Employees with Bipolar Disorder: Analysis of AHRQ 261 Specific Categories. Presented at the American Psychiatric Association Annual Meeting, May 24th, 2005. Atlanta, GA. 2005 Annual Meeting New Research Abstracts

Kleinman N, Brook RA, Gardner H, Rajagopalan K, and Smeeding J. Incremental Health Benefits Cost of Bipolar Disorder among Insured Employees. Presented at the International Society of Pharmacoeconomics and Outcomes Research 10th Annual Meeting. Washington, DC. May 17, 2005. Value Health, November 2005. 8(6):A237

Brook RA, Novak S, Kleinman N, Rajagopalan K, Gardner H, Smeeding JE. Annual Total Medical Costs For Bipolar Disorder Patients Treated With Antipsychotics. Presented AMCP Spring Educational Meeting, April 7, 2006. Seattle, WA. J Manag Care Pharm. 2006. Mar;12(2):174-175

Kleinman NL, Rajagopalan K, Brook RA, Novak S, Smeeding JE, Gardner HH. Changes in Mental Health-Related Insurance Claims Costs Among Patients Treated for Bipolar Disorder. American Psychiatric Association. Presented May 24, 2006. Toronto, Canada. 2006 Annual Meeting New Research Abstracts p 337

Brook RA, Rajagopalan K, Novak S, Kleinman NL, Smeeding JE, Gardner HH. Lost Work Days and Emergency Department Visits among Patients Treated for Bipolar Disorder. Presented American Psychiatric Association May 24, 2006. Toronto, Canada. 2006 Annual Meeting New Research Abstracts p 315-316

Rajagopalan K, Kleinman NL, Brook RA, Smeeding JE, Novak S, Gardner HH. Likelihood of employment termination for employees with Bipolar Disorder treated with different psychotropic Medications. International Society of Pharmacoeconomics and Outcomes Research (ISPOR).. May 22, 2006. Philadelphia, PA. Value Health. May 2006:9(3):A73

Brook RA, Kleinman NL, Melkonian AK, Smeeding JE. Hourly and Annual Objective Productivity (Presenteeism) Across Several Diseases: Bipolar Disorders, Chronic Constipation, Functional Dyspepsia, GERD, Gout, and Insomnia. ISPOR’s 14th Annual International Meeting, May 16-20, 2009, Orlando, FL. Value Health. 2009: 12(3):A169-70

Brook RA, Kleinman NL, Melkonian AK, Smeeding JE. Comparisons of Employee Workers’ Compensation Costs and Absence Days Using a National Database.Value Health 2010;13(3):A90

Brook RA, Kleinman NL, Melkonian AK, Smeeding JE. Incremental Sick Leave Costs and Lost Time Among Employees with Psychiatric and Medical Conditions. ISPOR’s 14th Annual International Meeting, May 16-20, 2009, Orlando, FL. Value Health. 2009:12(3):A87-8

Brook RA, Kleinman NL, Melkonian AK, Smeeding JE. Comparisons of Employee Workers’ Compensation Costs and Absence Days Using a National Database. J Manag Care Pharm. March 2010; 16(2):145-6

GERD / ARD:

Brook RA, Campbell S, Wahlqvist P, Wallander M, Kleinman NL, Wiklund I, Smeeding JE. Cost of illness of Gastroesophageal Reflux Disease (GERD): Comparison of medical, pharmacy, sick leave, short- and long-term disability, and workers’ compensation claims and medical claims by place of service between employees with and without GERD. American Gastroenterological Association. Oral Presentation, Digestive Disease Week: May 21, 2006. 2:15-2:30, Los Angeles, CA. Gastroenterology. April 2006;130(suppl2):A-27

Brook RA; Campbell S; Wahlqvist P; Wallander M; Kleinman NL, Wiklund I, Smeeding, JE. Cost of illness to the employer of Gastroesophageal Reflux Disease (GERD): Comparison of medical, pharmacy, sick leave, short- and long-term disability, and workers’ compensation claims and medical claims by place of service between employees with and without GERD. International Society of Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting May 22, 2006. Philadelphia, PA. Value Health. May 2006:9(3):A46

Wahlqvist P; Brook RA; Campbell S; Wallander M; Wiklund I, Kleinman NL, Smeeding, JE. Objective Measurement of Productivity While at Work in US Employees with and without Gastroesophageal Reflux Disease (GERD). International Society of Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting May 22, 2006. Philadelphia, PA. Value Health. May 2006:9(3):A49

Wahlqvist P, Brook RA, Campbell S, Wallander M, Kleinman NL, Wiklund I, Smeeding JE. Objective measurement of hourly and annual productivity while at work in employees with Gastroesophageal Reflux Disease (GERD) compared with employees without GERD. DDW, May 23, 2006. Los Angeles, CA. Gastroenterology. April 2006;130(suppl2):A-453

Brook RA, Smeeding JE, Joshua-Gotlib S, Warner D. Comparison of the Medication Possession Ratio Alone and in Combination with Breakthrough Events for Classifying Patients with Acid-Related Diseases. Presented at the International Society for Pharmacoeconomics and Outcomes Research 10th Annual Meeting, Washington, DC. Value Health. May 2005:8(3):373

Crawley JA, Brook R, Smeeding J. Retrospective Analysis of Switching from a Twice-Daily Proton Pump Inhibitor to Once-Daily Esomeprazole. Presented at the American College of Gastroenterology Annual Meeting, Fall 2004. Am J Gastroenterology, October 2004:9(s10):S232

Wallander M, Wahlqvist P, Kleinman NL, Campbell S, Talley NJ, Brook RA. Comorbidities during the year following diagnosis for persons with and without GERD using the Agency for Health Research and Quality (AHRQ) 261 Specific Categories. Presented The International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 12th Annual International Meeting, Arlington, VA: May 22, 2007.Value Health. May 2007:10(3):A147

Brook RA, Kleinman NL, Melkonian AK, Smeeding JE. Comparisons of Relative Risks of Serious Comorbidities Among Employees with and without Insomnia, GERD, Hepatitis C, Multiple Sclerosis and Chronic Constipation. Presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 13th Annual International Meeting, May 5, 2008 Toronto, Ontario, Canada. Value Health. May 2008:11(3):A44.

Brook RA, Kleinman NL, Melkonian AK, Smeeding JE. Comparisons of Employee Workers’ Compensation Costs and Absence Days Using a National Database.Value Health 2010;13(3):A90

Brook RA, Kleinman NL, Melkonian AK, Smeeding JE. Comparisons of Employee Workers’ Compensation Costs and Absence Days Using a National Database. J Manag Care Pharm. March 2010; 16(2):145-6

Gout:

Kleinman NL, Patel PA, Brook RA, Melkonian AK, Smeeding JE, Joseph-Ridge N. Economic Burden of Gout to the Employer. Presented at the Academy of Managed Care Pharmacy 2005 Educational Conference, October 7, 2005, Nashville, TN. J Manag Care Pharm. 2005. Sep;11(7):601

Kleinman NL, Patel PA, Brook RA, Melkonian AK, Smeeding JE, Joseph-Ridge N. Lost Days and Productivity Impact of Gout. Presented at the American College of Rheumatology (ACR) / ARHP Annual Scientific Meeting in San Diego, California, Program Number: (548) 1772, November 16, 2005, San Diego, CA

Kleinman NL, Brook RA, Patel PA, Melkonian AK, Smeeding JE, Joseph-Ridge N. Cost comparisons by place of service for persons with and without gout. Presented at the American Society of Health-System Pharmacists (ASHP) Mid-Year Meeting, Poster #438. December 2005, Las Vegas, NV

Novak S, Patel PA, Kleinman NL, Brook RA, Melkonian AK, Smeeding JE, Joseph-Ridge N. A comparison of average annual medical services for comorbid conditions associated with metabolic syndrome found in employees with gout versus those without gout: AMCP Spring Meeting. Presented: April 7, 2006. Seattle, WA. J Manag Care Pharm. 2006. Mar;12(2):173

Brook RA, Kleinman NL, Melkonian AK, Smeeding JE. Comparisons of Employee Workers’ Compensation Costs and Absence Days Using a National Database.Value Health 2010;13(3):A90

Annual Objective Productivity (Presenteeism) Across Several Diseases: Bipolar Disorders, Chronic Constipation, Functional Dyspepsia, GERD, Gout, and Insomnia. ISPOR’s 14th Annual International Meeting, May 16-20, 2009, Orlando, FL. Value Health. 2009: 12(3):A169-70

Brook RA, Kleinman NL, Melkonian AK, Smeeding JE. Comparisons of Employee Workers’ Compensation Costs and Absence Days Using a National Database. J Manag Care Pharm. March 2010; 16(2):145-6

Pain:

Novak S, Joshua-Gotlib S. Kleinman NL, Brook RA, Krueger K, Smeeding JE. Work productivity loss among those with Painful Conditions. Accepted American Pain Society (APS). #956. Presented: May 4-6, 2006. San Antonio, TX. The Journal of Pain, 2006. Vol. 7(4, Supp 1): 88. The Journal of Pain, 2006. Vol. 7(4, Supp 1): 88

Narayana A, Brook RA. A Healthcare Claims Database Analysis to Estimate the Prevalence of Chronic Opioid Use by Adult Patients in the United States.Pain Med 2009;10(1):abstract 278

Vo P, Brook RA, Kleinman NL, Strassels S, Smeeding JE, Best A, Lockhart E, Marx S. Work absence and absence costs in patients with osteoarthritis (OA) and low back pain (LBP) in the United States.J Pain. April 2010. 11(4) Suppl1:S8

Respiratory - Asthma, COPD, Respiratory Distress Syndrome:

Kleinman NL, Brook RA, Ramachandran S, Wagner S. Pediatric Asthma: An Employer Perspective on Annual Employee and Dependent Costs for Medical Care and Prescription Drugs. Presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 13th Annual International Meeting, May 6, 2008 Toronto, Ontario, Canada. Value Health May 2008:11(3):A273.

Marsh W, Smeeding J, York J, Sekar K, Ramanthan R. Cost-minimization Analysis of Treatment for Respiratory Distress Syndrome. Presented at the American Society for Health Systems Pharmacists, Mid-Year Meeting, 2003

Marsh W, Smeeding J, York J, Ramanthan R, Sekar K. Cost-minimization Analysis of Two Surfactant Treatments for Respiratory Distress Syndrome. Presented at the American Society for Health Systems Pharmacists, Mid-Year Meeting, 2004

York JM, Smeeding J, Brook R, Wong L, Leady M, Kagerman L, Klein G. A Retrospective Economic Comparison of Combined Ipratroprium Bromide and Albuterol versus Individual Components in Chronic Obstructive Pulmonary Disease (COPD) Patients. Presented at the Academy of Managed Care Pharmacy 17th Annual Meeting, April 23rd, 2005, Denver CO. J Manag Care Pharm. April 2005;11(3):279

Quintile Analysis:

Brook RA, Kleinman NL, Smeeding JE, Rajagopolan K, Wahlqvist P, Joshua-Gotlib S, George S, Cambell S, Wingenbach D, Krueger K, Melkonian AK, Novak S, Gardner HH. The Use of Quintile Analysis as a Measure of Disease Severity: A Comparison Within and Across Diseases. International Society of Pharmacoeconomics and Outcomes Research (ISPOR) as poster #PMC9. Presented May 22, 2006. Philadelphia, PA. Value Health. May 2006:9(3):A58

IVR systems:

Brook RA, Smeeding JE, Sachse SL, Cook J, Novak S. Multilingual Interactive Voice Response System for Patient Reported Outcomes in Multiple Countries. Presented at the AMAI Clinical Trials Expo 2005. October 24, 2005. Washington DC

Constipation / IBS:

Brook RA, Kleinman NL, Melkonian AK, Baran RW. Annual Direct and Indirect Cost of Illness in Employees with Irritable Bowel Syndrome plus Constipation. American College of Gastroenterology Annual Meeting, October 3-8, 2008, Orlando, FL. Am J Gastroenterol. 2008 Sep;103(S1):S381

Brook RA, Kleinman NL, Melkonian AK, Talley NJ, Locke, GR, Baran RW. The Prevalence and Costs to Treat Comorbidities in Persons with Constipation and Irritable Bowel Syndrome with Constipation in the 6 Months After Diagnosis: An Employer Perspective. American College of Gastroenterology Annual Meeting, October 3-8, 2008, Orlando, FL. Am J Gastroenterol. 2008 Sep;103(S1):S459-460

Ahn J, Nichol M, Brook RA, McCombs J, Baran RW. Cost estimates of chronic constipation in California Medicaid (Medi-Cal) patients. Presented at the Academy of Managed Care Pharmacy (AMCP) 19^th Spring Educational Meeting and Showcase, San Diego, CA. April 11-14, 2007.J Manag Care Pharm. 2007. Mar;13(2):174-175

Kleinman NL, Brook RA, Melkonian AK, Evans S, Talley NJ, Baran RW. Direct cost similarities by point of service for persons with Constipation and Irritable Bowel Syndrome with Constipation in the 6 Months Before and After Diagnosis: An employer perspective. Presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 13th Annual International Meeting, May 5, 2008 Toronto, Ontario, Canada. Value Health. May 2008:11(3):A86-87.

Brook RA, Kleinman NL, Melkonian AK, Smeeding JE. Comparisons of Relative Risks of Serious Comorbidities Among Employees with and without Insomnia, GERD, Hepatitis C, Multiple Sclerosis and Chronic Constipation. Presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 13th Annual International Meeting, May 5, 2008 Toronto, Ontario, Canada. Value Health. May 2008:11(3):A44.

Ahn J, Brook RA, Nichol MB, McCombs J, Talley NJ, Locke, GR, Baran RW. Similarities between Constipation with and without Irritable Bowel Syndrome in a Medicaid population: Costs trends by category in the 12 months after diagnosis from 1997 to 2002 using a random sample of California Medicaid (Medi-Cal) data. Digestive Disease Week 2008 (429080), presented May 20, 2008, San Diego, CA. Gastroenterology (2008), Vol. 133, No. 4

Kleinman NL, Brook RA, Melkonian AK, Baran RW. Direct costs by point of service for persons with and without constipation: An employer perspective. Presented at the Academy of Managed Care Pharmacy (AMCP) 19^th Spring Educational Meeting and Showcase, San Diego, CA. April 11-14, 2007.J Manag Care Pharm. 2007. Mar;13(2):177

Ahn J, Talley NJ, Brook RA, Nichol MB, McCombs J, Baran RW. Constipation in a Medicaid population: Trends in prevalence, age, gender, and costs in the 12 months after diagnosis from 1997 to 2002 using a random sample of California Medicaid (Medi-Cal) data. Gastroenterology (2007), Vol. 132, No. 4, Suppl 2, A-678

Medicaid Constipation Research presented at DDW: Constipation Costs May Be Straining the Health Care System (included video clip): Click For Link

Brook RA, Talley NJ, Kleinman NK, Baran RW. Functional gastrointestinal disorder comorbidities: Comparisons of prevalence and costs in the 6 months before and after diagnoses of constipation (C) and irritable bowel syndrome and constipation (IBS+C). Am J Gastroenterol. Sep 2007; 102(suppl2):S510

Kleinman NK, Brook RA, Melkonian AK, Baran RW, Talley NJ. Medical, Pharmacy, and Sick Leave Costs for Constipation and for Irritable Bowel Syndrome with Constipation in the 6 Months Before and After Diagnosis: An Employer Perspective. Am J Gastroenterol. Sep 2007; 102(suppl2):S451-452

Brook RA, Kleinman NL, Melkonian AK, Baran RW. Cost of Illness for Constipation: Medical, Pharmacy, and Work Absence Costs in Employees With or Without Constipation.. Am J Gastroenterol. Sep 2006; 101(suppl2):S408

Brook RA, Kleinman NL, Melkonian AK, Baran RW. The Prevalence and Costs to Treat GI Comorbidities in Persons with Constipation The American College of Gastroenterology Annual Scientific Meeting. Am J Gastroenterol. Sep 2006; 101(suppl2):S407-8

Kleinman NL, Brook RA, Melkonian AK, Baran RW. Healthcare Cost Comparisons by Point of Service for Persons With or Without Constipation. The American College of Gastroenterology Annual Scientific Meeting. Am J Gastroenterol. Sep 2006; 101(suppl2):S408

Kleinman NL, Brook RA, Melkonian AK, Baran RW. Assessment of Work Absences Associated with Constipation. The American College of Gastroenterology Annual Scientific Meeting. Am J Gastroenterol. Sep 2006; 101(suppl2):S409

Brook RA, Kleinman NL, Melkonian AK, Smeeding JE. Comparisons of Employee Workers’ Compensation Costs and Absence Days Using a National Database.Value Health 2010;13(3):A90

Brook RA, Kleinman NL, Melkonian AK, Smeeding JE. Comparisons of Employee Workers’ Compensation Costs and Absence Days Using a National Database. J Manag Care Pharm. March 2010; 16(2):145-6

Government Benefits / Medicaid:

Ahn J, Talley NJ, Brook RA, Nichol MB, McCombs J, Baran RW. Constipation in a Medicaid population: Trends in prevalence, age, gender, and costs in the 12 months after diagnosis from 1997 to 2002 using a random sample of California Medicaid (Medi-Cal) data. . Gastroenterology (2007), Vol. 132, No. 4, Suppl 2, A-678

Functional Dyspepsia:

George S, Kleinman NL, Brook RA, Smeeding JE. Impact of the ROME II criteria - assessment of related comorbid prevalence and costs of patients with functional dyspepsia. Presented at Digestive Disease Week (the American Gastroenterological Association) as poster # W1062, 226544, May 24, 2006. Los Angeles, CA. Gastroenterology. April 2006;130(suppl2):P-314 Abstract W1062

George S, Kleinman N, Brook R, Smeeding J. Costs of Functional Dyspepsia—Results from a large US Employer Database. Podium presentation, ISPOR’s 9^th Annual European Congress, October 30, 2006, Copenhagen, Denmark.Value Health. November/December 2006. 9(6):A189-90.

Brook RA, Kleinman NL, Melkonian AK, Smeeding JE. Comparisons of Employee Workers’ Compensation Costs and Absence Days Using a National Database. J Manag Care Pharm. March 2010; 16(2):145-6

Brook RA, Kleinman NL, Choung RS, Melkonian AK, Smeeding J, Talley NJ. Functional Dyspepsia Decrease Productivity and Increased Medical Costs. Value Health 2010;13:A70-71

Brook RA, Talley NJ, Choung RS, Melkonian AK, Smeeding J, Kleinman NL. Prevalence, Costs and Services of Comorbid conditions associated with Functional Dyspepsia. Value Health 2010;13:A71

Brook RA, Talley NJ, Choung RS, Smeeding JE, Kleinman NL. The Likelihood of Having Functional Dyspepsia Based on Other Comorbid Conditions. Value Health 2011:14(3):A180

Insomnia And Sleep Disorders:

Brook RA, Kleinman NL, Melkonian AK, Doan JF, Baran RW. Cost of illness for insomnia: medical, pharmacy, and work absence costs in employees with or without insomnia. Sleep 2007; 30(suppl):A246

Kleinman NL, Brook RA, Melkonian AK, Doan JF, Baran RW. Assessment of Work Absences Associated with Insomnia. Presented at the Academy of Managed Care Pharmacy’'s (AMCP) 2007 Educational Conference, Boston, MA, October 26, 2007. J Manag Care Pharm. Sep 2007;13(8):690

Brook RA, Kleinman NL, Melkonian AK, Doan JF, Baran RW. Healthcare Cost Comparisons by Point-of-Service for Employees with or without Insomnia. Presented at the Academy of Managed Care Pharmacy’'s (AMCP) 2007 Educational Conference, Boston, MA, October 26, 2007. J Manag Care Pharm. Sep 2007:13(8):701.

Insomnia Research Presented at SLEEP2007:
APSS: Extra Health Cost of Insomnia Reaches $3,200 an Employee (includes video clip) Click For Link

Doan JF, Brook RA, Kleinman NL, Melkonian AK, Smeeding JE, Baran RW. Objective Costs and Prevalence of Comorbidities for Persons with and without Insomnia. Presented at the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 10th Annual European Congress, Dublin, Ireland October 22, 2007. Value Health November/December 2007. 10(6): A384-385

Brook RA, Kleinman NL, Melkonian AK, Smeeding JE. Comparisons of Employee Workers’ Compensation Costs and Absence Days Using a National Database.Value Health 2010;13(3):A90

Brook RA, Kleinman NL, Melkonian AK, Smeeding JE. Comparisons of Employee Workers’ Compensation Costs and Absence Days Using a National Database. J Manag Care Pharm. March 2010; 16(2):145-6

Rheumatoid Arthritis:

Kleinman NL, Brook RA, Kirbach SE, Cifaldi MA. Costs and Absences Associated with Rheumatoid Arthritis On Work Productivity: A Comparison Between Employees with and without Rheumatoid Arthritis In a United States Population. Arthritis Rheum. Oct 2011. 63(10—Sup):S359.

Manuscripts Published:

Rheumatology: Rheumatoid Arthritis and Gout

Brook RA, Kleinman NL, Patel PA, Melkonian AK, Brizee TJ, Smeeding JE, Joseph-Ridge N. The economic burden of gout on an employed population. Curr Med Res Opin. 2006 Jul;22(7):1381-9

Novak S, Melkonian AK, Patel PA, Kleinman NL, Joseph-Ridge N, Brook RA. Metabolic syndrome-related conditions among people with and without gout: prevalence and resource use. Curr Med Res Opin. 2007 Mar;23(3):623-30

Kleinman NL, Brook RA, Patel PA, Melkonian AK, Smeeding JE, Joseph-Ridge N. Lost time and Reduced Productivity Associated with Gout. Value Health. 2007 Jul-Aug;10(4):231-7

Brook RA, Forsythe A, Smeeding JE, Edwards NL. Chronic gout: epidemiology, disease progression, treatment and disease burden. Curr Med Res Opin. 2010: 26(12): 2813–2821

Kleinman NL, Cifaldi MA, Smeeding JE, Shaw JW, Brook RA. Annual Incremental Health Benefit Costs and Absenteeism Among Employees with and Without Rheumatoid Arthritis. J Occup Environ Med. March 2013; 55(3):240-244.

Click here for Press Release

Bipolar Disorder:

Rajagopalan K, Kleinman NL, Brook RA, Gardner HH, Brizee TJ, Smeeding JE. Costs of physical and mental comorbidities among employees: a comparison of those with and without bipolar disorder. Curr Med Res Opin. 2006 Mar;22(3):443-52

Kleinman NL, Brook RA, Rajagopalan K, Gardner HH, Brizee TJ, Smeeding JE. Lost time, absence costs, and reduced productivity output for employees with bipolar disorder.J Occup Environ Med. 2005 Nov;47(11):1117-24

Brook RA, Rajagopalan K, Kleinman NL, Smeeding JE, Brizee TA; Gardner HH. Incurring Greater Health Care Costs: Risk Stratification of Bipolar Disorder Employees. Prim Care Companion J Clin Psychiatry.2006;8(1):17-24

Gardner HH, Kleinman NL, Brook RA, Rajagopalan K, Brizee TJ, Smeeding JE. The economic impact of bipolar disorder in an employed population from an employer perspective. J Clin Psychiatry 2006 Aug;67(8):1209-18

Brook RA, Kleinman NL, Rajagopalan K. Employee costs before and after treatment initiation for bipolar disorder. Am J Manag Care. 2007 Apr;13(4):179-86

ESRD / K /DOQI:

Pai AB, Smeeding JE, Brook RA. The role of sevelamer in achieving the kidney disease outcomes quality initiative (K/DOQI) guidelines for hyperphosphatemia. Curr Med Res Opin. 2004 Jul;20(7):991-9

Functional Dyspepsia:

Brook RA, Kleinman NL, Choung RS, Melkonian AK, Smeeding JE, Talley NJ. Functional Dyspepsia Impacts Absenteeism and Direct and Indirect Costs. Clin Gastroenterol Hepatol. 2010 Jun;8(6):498-503

Brook RA, Kleinman NL, Choung RS, Smeeding JE, Talley NJ. Excess Comorbidity Prevalence and Cost Associated with Functional Dyspepsia in an Employed Population. Dig Dis Sci 2012. 57(1):109–118. Epub 2011 Jul 13.

COPD / Asthma:

York JM, Smeeding J, Brook RA, Hoehler F, Klein GL. Exploratory Economic Evaluation of Patients With COPD on a Combination Product Versus Individual Components (Ipratropium Bromide and Albuterol). Adv Ther. 2007 Jul-Aug;24(4):757-771

Kleinman NL, Ramachandran S, Brook RA. Health Benefit Cost of Employees with Children with Asthma. Ann Allergy Asthma Immunol. August 2009;103:114–120

GERD / ARD:

Brook RA, Wahlqvist P, Kleinman NL, Wallander M-A, Campbell SM, Smeeding JE. Cost gastro-oesophageal reflux disease to the employer: a US perspective. Aliment Pharmacol Ther. 2007. 26(6):889-898

Wahlqvist P, Kleinman NL, Brook RA, Wallander M-A, Campbell SM, Smeeding JE. Objective measurement of work absence and on-the-job productivity: a case-control study of US employees with and without gastroesophageal reflux disease. J Occup Environ Med. 2008;50:25-31.

Multiple Sclerosis:

Brook RA, Rajagopalan K, Kleinman NL, Melkonian AK. Absenteeism and Health Benefit Costs Among Employees with Multiple Sclerosis.Curr Med Res Opin; June 2009;25(6):1469–76.

Kleinman NL, Beren IA, Rajagopalan K, Brook RA. Medication adherence with disease modifying treatments for multiple sclerosis among US employees. J Med Econ. 2010 Oct 19. 13(4):633-640 [Epub ahead of print]

Rajagopalan K, Brook RA, Beren IA, Kleinman NL. Comparing costs and absences for Multiple Sclerosis among US employees: pre- and post-treatment initiation. Curr Med Res Opin. 2011 Jan;27(1):179–188.

Insomnia and Sleep Disorders:

Kleinman NL, Brook RA, Melkonian AK, Doan JF, Baran RW. Health Benefit Costs and Absenteeism due to Insomnia from the Employer’s Perspective. J Clin Psychiatry 2009;70(8):1098-1104

Hepatitis C:

Su J, Brook RA, Kleinman NL, Corey-Lisle P. The Impact of Hepatitis-C Viral (HCV) Infection on Work Absence, Productivity, and Healthcare Benefit Costs. Hepatology. 2010;52:436-442.

Brook RA, Kleinman NL, Su J, Corey-Lisle PK, Iloeje UH. Absenteeism and Productivity Among Employees Being Treated for Hepatitis C. Am J Manag Care. October 2011;17(10):657-664.

Women's Health (Endometriosis):

Fuldeore MJ, Marx SE, Chwalisz K, Smeeding JE, Brook RA. Add-back therapy use and its impact on LA persistence in patients with endometriosis. Curr Med Res Opin. 2010 Mar;26(3):729-36.

Good Research Practices:

Hay JW, Smeeding J, Carroll NV, Drummond M, Garrison LP, Mansley EC, Mullins CD, Mycka JM, Seal B, Shi L. Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force report--Part I. Value Health. 2010 Jan-Feb;13(1):3-7. doi: 10.1111/j.1524-4733.2009.00663.x. Epub 2009 Oct 28. PubMed PMID: 19874571. Link: http://www.ncbi.nlm.nih.gov/pubmed/19874571

Garrison LP Jr, Mansley EC, Abbott TA 3rd, Bresnahan BW, Hay JW, Smeeding J. Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective: the ISPOR Drug Cost Task Force report--Part II. Value Health. 2010 Jan-Feb;13(1):8-13. doi: 10.1111/j.1524-4733.2009.00660.x. Epub 2009 Oct 23. PubMed PMID: 19883405. Link: http://www.ncbi.nlm.nih.gov/pubmed/19883405

Mansley EC, Carroll NV, Chen KS, Shah ND, Piech CT, Hay JW, Smeeding J. Good research practices for measuring drug costs in cost-effectiveness analyses: a managed care perspective: the ISPOR Drug Cost Task Force report--Part III. Value Health. 2010 Jan-Feb;13(1):14-7. doi: 10.1111/j.1524-4733.2009.00661.x. Epub 2009 Oct 26. PubMed PMID: 19883404. Link: http://www.ncbi.nlm.nih.gov/pubmed/19883404

Mullins CD, Seal B, Seoane-Vazquez E, Sankaranarayanan J, Asche CV, Jayadevappa R, Lee WC, Romanus DK, Wang J, Hay JW, Smeeding J. Good research practices for measuring drug costs in cost-effectiveness analyses: Medicare, Medicaid and other US government payers perspectives: the ISPOR Drug Cost Task Force report--Part IV. Value Health. 2010 Jan-Feb;13(1):18-24. doi: 10.1111/j.1524-4733.2009.00604.x. Epub 2009 Oct 6. PubMed PMID: 19807903. Link http://www.ncbi.nlm.nih.gov/pubmed/19807903

Mycka JM, Dellamano R, Kolassa EM, Wonder M, Ghosh S, Hay JW, Smeeding J. Good research practices for measuring drug costs in cost effectiveness analyses: an industry perspective: the ISPOR Drug Cost Task Force report--Part V. Value Health. 2010 Jan-Feb;13(1):25-7. doi: 10.1111/j.1524-4733.2009.00664.x. Epub 2009 Oct 26. PubMed PMID: 19883402. Link: http://www.ncbi.nlm.nih.gov/pubmed/19883402

Shi L, Hodges M, Drummond M, Ahn J, Li SC, Hu S, Augustovski F, Hay JW, Smeeding J. Good research practices for measuring drug costs in cost-effectiveness analyses: an international perspective: the ISPOR Drug Cost Task Force report--Part VI. Value Health. 2010 Jan-Feb;13(1):28-33. doi: 10.1111/j.1524-4733.2009.00662.x. Epub 2009 Oct 26. PubMed PMID: 19883403. Link http://www.ncbi.nlm.nih.gov/pubmed/19883403